Exciting News on Product Development Achievements: Shijiazhuang Sihua Pharmaceutical Group’s Polypropylene Infusion Bottle Packaging for Metronidazole Sodium Chloride Injection Has Been Approved.
Category:
发布时间:2022-09-07
【概要描述】
Following the successful acquisition of the active pharmaceutical ingredient for argatroban and the approval of the country’s first manufacturing license for azithromycin dry suspension, Shijiazhuang Sihua Pharmaceutical Group has once again achieved a significant milestone in product development: its applications for two specifications of metronidazole sodium chloride injection in polypropylene infusion bottles—250 mL: 1.25 g and 100 mL: 0.5 g—have been granted drug production registration approvals.
Following the successful acquisition of the active pharmaceutical ingredient for argatroban and the approval of the country’s first manufacturing license for azithromycin dry suspension, Shijiazhuang Sihua Pharmaceutical Group has once again achieved a significant milestone in product development: its applications for two specifications of metronidazole sodium chloride injection in polypropylene infusion bottle packaging—250 mL: 1.25 g and 100 mL: 0.5 g—have been granted drug production registration approvals. This approval will further diversify the packaging options within the metronidazole product line, thereby meeting the needs of various customer segments.
According to reports, the newly approved product builds upon the originally approved multi-layer co-extruded film infusion bag that had already passed the consistency evaluation by adding plastic bottle packaging. Metronidazole is a commonly used antibiotic primarily indicated for the treatment or prevention of systemic or local infections caused by anaerobic bacteria, including infections of the abdominal cavity, gastrointestinal tract, female reproductive system, and oral cavity.
Meanwhile, the Group has received approval from the National Medical Products Administration to manufacture the corresponding finished dosage form—rosuvastatin calcium tablets—using its self-produced rosuvastatin calcium API. Previously, Shijiazhuang Sihua Pharmaceutical Group’s applications for both the rosuvastatin calcium API and rosuvastatin calcium tablets were successively granted manufacturing approvals. Rosuvastatin calcium is primarily indicated for the treatment of primary hypercholesterolemia or mixed dyslipidemia.
Keywords:
Recommended News
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091